SEARCH

SEARCH BY CITATION

References

  • 1
    Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 3: 6924.
  • 2
    European Medicines Agency. Guideline on Clinical Investigation of Medicinal Products for Prophylaxis of Venous Thromboembolic Risk in Non-Surgical Patients. London: European Medicines Agency, 2006. ( http://www.emea.europa.eu/pdfs/human/ewp/623504en.pdf. Accessed 8 June 2009.)
  • 3
    Hull RD, Yusen R, Bergqvist D. Assessing the safety profiles of new anticoagulants for major orthopedic surgery thromboprophylaxis. Clin Appl Thromb Hemost 2009; 15: 37788.
  • 4
    European Medicines Agency. Guideline on Clinical Investigation of Medicinal Products for Prophylaxis of High Intra- and Post-Operative Venous Thromboembolic Risk. London: European Medicines Agency, 2007. ( http://www.emea.europa.eu/pdfs/human/ewp/70798en_fin.pdf. Accessed 8 June 2009)
  • 5
    Dahl OE, Borris LC, Bergqvist D, Schnack Rasmussen M, Eriksson BI, Kakkar AK, Colwell CW, Caprini JA, Fletcher J, Friedman RJ, Lassen MR, Frostick SP, Sakon M, Kwong LM, Kakkar VV. Major joint replacement. A model for antithrombotic drug development: from proof-of-concept to clinical use. Int Angiol 2008; 27: 607.
  • 6
    Bergqvist D, Clement D. Adjudication of end points in studies on substances influencing haemostasis – an example from vascular surgery. Eur J Vasc Endovasc Surg 2008; 36: 7034.